BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab

Reuters10-06

BRIEF-<a href="https://laohu8.com/S/SKYE">Skye Bioscience</a> reports early trial data for Cbeyond combo and solo use of Nimacimab

Oct 6 (Reuters) - Skye Bioscience Inc SKYE.O:

SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND™ PHASE 2A DATA FROM NIMACIMAB MONOTHERAPY AND COMBINATION CLINICAL TRIAL
SKYE BIOSCIENCE INC - NIMACIMAB MONOTHERAPY FAILS TO MEET PRIMARY WEIGHT LOSS ENDPOINT
SKYE BIOSCIENCE INC - ADDITIONAL WEIGHT LOSS WITH NIMACIMAB AND SEMAGLUTIDE COMBINATION
SKYE BIOSCIENCE INC - NIMACIMAB ALONE & IN COMBINATION SHOWS CLEAN SAFETY PROFILE IN TRIAL
SKYE BIOSCIENCE INC - EXPECTS TO REPORT DATA FROM EXTENSION STUDY IN Q1 2026

Source text: ID:nGNX9XTdFZ

Further company coverage: SKYE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2573679448?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573679448","market":"fut","top_or_hot":-1,"title":"BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience</a> reports early trial data for Cbeyond combo and solo use of Nimacimab</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span>Skye Bioscience Inc <span>SKYE.O</span>:</p><ul><li><p>SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND™ PHASE 2A DATA FROM NIMACIMAB MONOTHERAPY AND COMBINATION CLINICAL TRIAL</p></li><li><p>SKYE BIOSCIENCE INC - NIMACIMAB MONOTHERAPY FAILS TO MEET PRIMARY WEIGHT LOSS ENDPOINT</p></li><li><p>SKYE BIOSCIENCE INC - ADDITIONAL WEIGHT LOSS WITH NIMACIMAB AND SEMAGLUTIDE COMBINATION</p></li><li><p>SKYE BIOSCIENCE INC - NIMACIMAB ALONE &amp; IN COMBINATION SHOWS CLEAN SAFETY PROFILE IN TRIAL</p></li><li><p>SKYE BIOSCIENCE INC - EXPECTS TO REPORT DATA FROM EXTENSION STUDY IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX9XTdFZ</span></p><p>Further company coverage: <span>SKYE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of Nimacimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-06 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/SKYE\">Skye Bioscience</a> reports early trial data for Cbeyond combo and solo use of Nimacimab</title></head><body><p><span>Oct 6 (Reuters)</span><span> - </span>Skye Bioscience Inc <span>SKYE.O</span>:</p><ul><li><p>SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND™ PHASE 2A DATA FROM NIMACIMAB MONOTHERAPY AND COMBINATION CLINICAL TRIAL</p></li><li><p>SKYE BIOSCIENCE INC - NIMACIMAB MONOTHERAPY FAILS TO MEET PRIMARY WEIGHT LOSS ENDPOINT</p></li><li><p>SKYE BIOSCIENCE INC - ADDITIONAL WEIGHT LOSS WITH NIMACIMAB AND SEMAGLUTIDE COMBINATION</p></li><li><p>SKYE BIOSCIENCE INC - NIMACIMAB ALONE &amp; IN COMBINATION SHOWS CLEAN SAFETY PROFILE IN TRIAL</p></li><li><p>SKYE BIOSCIENCE INC - EXPECTS TO REPORT DATA FROM EXTENSION STUDY IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX9XTdFZ</span></p><p>Further company coverage: <span>SKYE.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SKYE","symbol_name":"Skye Bioscience Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251006:nTUA6VGJ6S:1","article_id":"2573679448","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573679448","pubTimestamp":1759748904,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of NimacimabOct 6 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND PHASE 2A DATA FROM NIMACI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SKYE":"Skye Bioscience Inc.","BK4139":"生物科技"},"translate_title":"简介-Skye Bioscience报告Cbeyond组合和单独使用Nimacimab的早期试验数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SKYE":0.9},"content_text":"BRIEF-Skye Bioscience reports early trial data for Cbeyond combo and solo use of NimacimabOct 6 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE BIOSCIENCE REPORTS TOPLINE CBEYOND™ PHASE 2A DATA FROM NIMACIMAB MONOTHERAPY AND COMBINATION CLINICAL TRIALSKYE BIOSCIENCE INC - NIMACIMAB MONOTHERAPY FAILS TO MEET PRIMARY WEIGHT LOSS ENDPOINTSKYE BIOSCIENCE INC - ADDITIONAL WEIGHT LOSS WITH NIMACIMAB AND SEMAGLUTIDE COMBINATIONSKYE BIOSCIENCE INC - NIMACIMAB ALONE & IN COMBINATION SHOWS CLEAN SAFETY PROFILE IN TRIALSKYE BIOSCIENCE INC - EXPECTS TO REPORT DATA FROM EXTENSION STUDY IN Q1 2026Source text: ID:nGNX9XTdFZFurther company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2573679448","isCrawlerRequest":true}